Chesapeake Capital Corp IL Sells 1,387 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Chesapeake Capital Corp IL trimmed its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 50.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,339 shares of the biotechnology company's stock after selling 1,387 shares during the quarter. Chesapeake Capital Corp IL's holdings in Axon Enterprise were worth $394,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new position in Axon Enterprise in the 4th quarter worth approximately $195,406,000. Motley Fool Asset Management LLC boosted its holdings in Axon Enterprise by 238.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company's stock valued at $153,981,000 after purchasing an additional 346,838 shares during the period. 1832 Asset Management L.P. acquired a new stake in Axon Enterprise in the 1st quarter worth $81,630,000. Vanguard Group Inc. increased its holdings in shares of Axon Enterprise by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company's stock worth $2,547,878,000 after purchasing an additional 212,401 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Axon Enterprise by 110.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company's stock worth $71,302,000 after purchasing an additional 144,568 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Trading Down 1.4 %

Shares of AXON stock traded down $5.04 during trading hours on Tuesday, reaching $359.35. The company had a trading volume of 324,389 shares, compared to its average volume of 518,497. Axon Enterprise, Inc. has a 1-year low of $189.12 and a 1-year high of $378.89. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The firm has a market cap of $27.16 billion, a price-to-earnings ratio of 104.80, a P/E/G ratio of 9.50 and a beta of 0.94. The company has a 50 day moving average of $332.91 and a 200 day moving average of $312.13.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to analysts' expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company's revenue was up 34.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.80 earnings per share. On average, equities research analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Insider Activity at Axon Enterprise

In other news, CEO Patrick W. Smith sold 80,300 shares of Axon Enterprise stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the transaction, the chief executive officer now directly owns 3,015,366 shares of the company's stock, valued at $1,121,052,771.48. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Patrick W. Smith sold 80,300 shares of the company's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $371.78, for a total value of $29,853,934.00. Following the completion of the sale, the chief executive officer now owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Jeffrey C. Kunins sold 8,182 shares of the business's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $364.86, for a total value of $2,985,284.52. Following the completion of the transaction, the insider now directly owns 176,228 shares of the company's stock, valued at $64,298,548.08. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 286,832 shares of company stock worth $104,350,029. 6.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

AXON has been the subject of several recent research reports. Jefferies Financial Group initiated coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a "buy" rating and a $385.00 price target for the company. JMP Securities reiterated a "market outperform" rating and issued a $375.00 target price on shares of Axon Enterprise in a research note on Monday. Craig Hallum increased their target price on Axon Enterprise from $370.00 to $376.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $400.00 price target on shares of Axon Enterprise in a report on Wednesday, August 7th. Finally, Robert W. Baird increased their price objective on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an "outperform" rating in a report on Tuesday. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus target price of $361.15.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.